TSC2 基因突变与非小细胞肺癌根治术后预后的关系。
TSC2 genetic variant and prognosis in non-small cell lung cancer after curative surgery.
机构信息
Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.
Department of Biochemistry and Cell Biology, School of Medicine, Kyungpook National University, Daegu, South Korea.
出版信息
Thorac Cancer. 2019 Feb;10(2):335-340. doi: 10.1111/1759-7714.12951. Epub 2018 Dec 26.
This study was conducted to investigate the associations between polymorphisms of genes involved in the LKB1 pathway and the prognosis of patients with non-small cell lung cancer (NSCLC) after surgical resection. Twenty-three single nucleotide polymorphisms (SNPs) in the LKB1 pathway were investigated in 782 patients with NSCLC who underwent curative surgery. The association of SNPs with overall survival (OS) and disease-free survival (DFS) were analyzed. Among the 23 SNPs investigated, TSC2 rs30259G > A was associated with significantly worse OS and DFS (adjusted hazard ratio for OS 1.88, 95% confidence interval 1.21-2.91, P = 0.005; adjusted hazard ratio for DFS 1.65, 95% confidence interval 1.15-2.38, P = 0.01, under codominant models, respectively). Subgroup analysis showed that SNPs were significantly associated with survival outcomes in squamous cell carcinoma, ever-smokers, and stage I, but not in adenocarcinoma, never-smokers, and stage II-IIIA. The results suggest that TSC2 rs30259G > A may be useful to predict prognosis in patients with NSCLC, especially squamous cell carcinoma, after curative surgery.
本研究旨在探讨 LKB1 通路相关基因多态性与接受手术切除的非小细胞肺癌（NSCLC）患者预后之间的关系。对 782 例接受根治性手术的 NSCLC 患者的 LKB1 通路中 23 个单核苷酸多态性（SNP）进行了研究。分析了 SNP 与总生存期（OS）和无病生存期（DFS）的相关性。在研究的 23 个 SNP 中，TSC2 rs30259G > A 与 OS 和 DFS 显著相关（OS 的调整后的危险比为 1.88，95%置信区间为 1.21-2.91，P = 0.005；DFS 的调整后的危险比为 1.65，95%置信区间为 1.15-2.38，P = 0.01，在显性模型下）。亚组分析显示，SNP 与鳞状细胞癌、吸烟者和 I 期患者的生存结局显著相关，但与腺癌、不吸烟者和 IIA-IIIA 期患者的生存结局无关。结果表明，TSC2 rs30259G > A 可能有助于预测接受根治性手术后 NSCLC 患者的预后，尤其是鳞状细胞癌患者的预后。
Zotero 插件